ANIP
ANI Pharma
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 347.78M; Volume: 8.68K; AvgVol 3m: 86.77K; Beta: 1.26;
Cost estimate:
P/E: –; EPS: -1.70; EPS growth quarter/prev quarter: -295.20%;
EPS growth this year: -61.80%; EPS growth past 5 years: -28.10%;
EPS ttm: -1.70;
P/S: 1.80; P/B: 1.82; P/Cashflow: 12.82; P/FCF: 8.12;
Sales: 197.55M; Sales growth quarter/prev quarter: -10.80%; Sales growth past 5 years: 29.80%;
Profitability:
Gross Margin: 61.90%; Profit Margin: -10.30%; Operating Margin: -8.30%;
ROA – return on assets: -4.40%; ROE – return on equity: -9.90%; LT Debt/Equity: 0.93; Total Debt/Equity: 0.99;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 4.60%; Insider Transactions:1.81%;
Institutional Ownership: 80.70%; Institutional Transactions: -6.52%;
Data update: 07/10/2020.